Scholarlink

<p>Cocktail therapy significantly reduces the development of resistance to individual medications due to viral mutations. However, for effective inhibition of a particular virus, a customized approach to combination pharmacotherapy may be essential. Porcine epidemic diarrhea virus (PEDV) is a member of the Coronaviridae family, whose genome consists of a single strand of positive-sense RNA and has evolved into multiple epidemic lineages with no available drugs in clinical practice. In this study, we found that the nucleoside analog gemcitabine decreased the titer of PEDV, with a median effective concentration (EC<sub>50</sub>) of 3.12 μM, thereby inhibiting viral replication. The natural product baicalein acts by targeting the early entry stage and directly inactivates the virus, with an EC<sub>50</sub> of 5.02 μM. A notable synergistic effect was observed with the combination of 1 μM gemcitabine and 1.5 μM baicalein. This study demonstrated that the strategic use of a drug combination targeting both the replication and entry phases of the PEDV lifecycle can effectively inhibit viral proliferation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gemcitabine combined with baicalein exerts antiviral activity against PEDV by inhibiting the entry and replication phases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月6日

查看全文
  • Yingge Zheng,
  • Yanfei Zhang,
  • Fangying Xiong,
  • Dehua Luo,
  • Yuxiang Wang,
  • Yijia Zhang,
  • Dengguo Wei

摘要

Cocktail therapy significantly reduces the development of resistance to individual medications due to viral mutations. However, for effective inhibition of a particular virus, a customized approach to combination pharmacotherapy may be essential. Porcine epidemic diarrhea virus (PEDV) is a member of the Coronaviridae family, whose genome consists of a single strand of positive-sense RNA and has evolved into multiple epidemic lineages with no available drugs in clinical practice. In this study, we found that the nucleoside analog gemcitabine decreased the titer of PEDV, with a median effective concentration (EC50) of 3.12 μM, thereby inhibiting viral replication. The natural product baicalein acts by targeting the early entry stage and directly inactivates the virus, with an EC50 of 5.02 μM. A notable synergistic effect was observed with the combination of 1 μM gemcitabine and 1.5 μM baicalein. This study demonstrated that the strategic use of a drug combination targeting both the replication and entry phases of the PEDV lifecycle can effectively inhibit viral proliferation.